Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease (Q39373577)

11 September 2017

Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease (English)

1 reference

11 September 2017

1 reference

D Marchesan

1

1 reference

PubMed ID

22450713

11 September 2017

T M Cox

series ordinal

2

1 reference

PubMed ID

22450713

11 September 2017

P B Deegan

series ordinal

3

1 reference

11 September 2017

24 March 2012

1 reference

Journal of Inherited Metabolic Disease

11 September 2017

1 reference

11 September 2017

35

1 reference

11 September 2017

6

1 reference

11 September 2017

1107-1117

1 reference

https://scigraph.springernature.com/pub.10.1007/s10545-012-9472-3

11 September 2017

0 references

cites work

Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

A guided tour into subcellular colocalization analysis in light microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Narrative review: Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Neutral glycosphingolipids of serum lipoproteins in Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Growth and hepatospecific gene expression of human hepatoma cells in a defined medium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Natural history of Fabry disease in females in the Fabry Outcome Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Enzyme replacement and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

The mousetrap: what we can learn when the mouse model does not mimic the human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

CNS manifestations of Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Mannose 6-phosphate receptors: new twists in the tale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Magnetic resonance imaging changes in Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Enzyme therapy for lysosomal storage disease: principles, practice, and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Stroke in Fabry's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Early renal changes in hemizygous and heterozygous patients with Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

A syntaxin 1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve terminal: analysis by quantitative immunocolocalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Origins of circulating endothelial cells and endothelial outgrowth from blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Use of blood outgrowth endothelial cells for gene therapy for hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

The cerebral vasculopathy of Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Establishment and characterization of Fabry disease endothelial cells with an extended lifespan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Monitoring biodistribution of glycoproteins with modified sugar chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Toward closed-system culture of blood origin endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Cloning and characterization of the murine activin receptor like kinase-1 (ALK-1) homolog

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

An Atypical Ultrastructural Pattern in Fabry's Disease: A Study on Its Nature and Incidence in 7 Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9472-3

Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide

21 January 2018

1 reference

12 December 2020

Sequelae of storage in Fabry disease--pathology and comparison with other lysosomal storage diseases

1 reference

12 December 2020

Phagocytosis of unopsonized zymosan by human monocyte-derived macrophages: maturation and inhibition by mannan

1 reference

12 December 2020

Arterial remodelling in Fabry disease

1 reference

12 December 2020

Platelet/endothelial cell adhesion molecule-1 (CD31)-mediated cellular aggregation involves cell surface glycosaminoglycans.

1 reference

12 December 2020

Affinity purification of alpha-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. Properties of the purified splenic enzyme compared to other forms

1 reference

12 December 2020

Competitive time-resolved immunofluorometric assay for quantifying carbonic anhydrase VI in saliva

1 reference

12 December 2020

Fabry's disease: absence of storage as a feature of liver sinus endothelium

1 reference

12 December 2020

Enzyme replacement in Fabry endothelial cells and fibroblasts: uptake experiments and electron microscopical studies

1 reference

12 December 2020

Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice

1 reference

12 December 2020

Angiokeratoma corporis diffusum (Fabry disease).

1 reference

12 December 2020

Effects of cytochalasin D on shape and fluid pinocytosis in human neutrophils as related to cytoskeletal changes (actin, alpha-actinin and microtubules)

1 reference

12 December 2020

Stability of plasma low density lipoprotein with abnormal glycolipid composition from patients with Fabry's disease

1 reference

12 December 2020

Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy

1 reference

12 December 2020

Identification and validation of mannose 6-phosphate glycoproteins in human plasma reveal a wide range of lysosomal and non-lysosomal proteins

1 reference

12 December 2020

The preparation of subcellular organelles from mouse liver in self-generated gradients of iodixanol

1 reference

12 December 2020

Structural and functional changes in peripheral vasculature of Fabry patients

1 reference

12 December 2020

The glycosphingolipids of human plasma lipoproteins

1 reference

12 December 2020

Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease

1 reference

12 December 2020

Fluid phase endocytosis and galactosyl receptor-mediated endocytosis employ different early endosomes

1 reference

12 December 2020

10.1007/S10545-012-9472-3

Identifiers

DOI

1 reference

11 September 2017

1 reference

PubMed ID

22450713